2023
BSBM-16 HLA CLASS-I ANTIGEN PRESENTATION MACHINERY AND IFN-Îł PATHWAY ALTERATIONS IN LUNG CANCER BRAIN METASTASES
Vilarino N, de Rodas M, Lu B, Goldberg S, Schalper K. BSBM-16 HLA CLASS-I ANTIGEN PRESENTATION MACHINERY AND IFN-Îł PATHWAY ALTERATIONS IN LUNG CANCER BRAIN METASTASES. Neuro-Oncology Advances 2023, 5: iii4-iii4. PMCID: PMC10402438, DOI: 10.1093/noajnl/vdad070.012.Peer-Reviewed Original ResearchLung cancer brain metastasesPrimary lung tumorsImmune checkpoint inhibitorsCancer brain metastasesBrain metastasesPresentation machineryClinicopathologic variablesHLA classTumor cell PD-L1 expressionBackground Immune checkpoint inhibitorsLocal adaptive immune responseHLA Class I AntigenPD-L1 expressionDuration of responseB2MAdaptive immune responsesDistinct immunomodulatory propertiesImmune evasion mechanismsClass I AntigenIFN-Îł signalingIRF-1Interferon regulatory factor 1Checkpoint inhibitorsMost patientsWorse survivalRole of HLA class-I antigen peptide loading complex components in immune evasion and treatment sensitivity in human lung cancer.
Costantini A, Ranjan K, Ferrone S, Schalper K. Role of HLA class-I antigen peptide loading complex components in immune evasion and treatment sensitivity in human lung cancer. Journal Of Clinical Oncology 2023, 41: 2623-2623. DOI: 10.1200/jco.2023.41.16_suppl.2623.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsHLA classSelective downregulationShorter OSICI resistanceMarker levelsStromal cellsLow marker levelTumor antigen recognitionEffector T cellsT cell infiltrationT cell levelsProtein levelsPeptide loading complexEarly-stage tumorsHuman lung cancerPeptide-HLA complexesLevels of TAPDeterminants of sensitivityLow CD8Checkpoint inhibitorsHuman NSCLCPresentation machineryClinicopathologic variablesLung cancer
2017
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research 2017, 23: 370-378. PMID: 27440266, PMCID: PMC6350535, DOI: 10.1158/1078-0432.ccr-16-0150.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAgedB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaInterleukin-10Lymphocytes, Tumor-InfiltratingMiddle AgedNeoplasm StagingRNA, MessengerV-Set Domain-Containing T-Cell Activation Inhibitor 1ConceptsNon-small cell lung cancerB7-H4PD-L1IDO-1Lung cancerLung carcinomaQuantitative immunofluorescenceIFNÎł stimulationElevated PD-L1Major clinicopathologic variablesMultiplexed quantitative immunofluorescenceOptimal clinical trialsT-cell infiltratesCell lung cancerImmune evasion pathwaysHuman lung carcinomaLung adenocarcinoma A549Cancer Genome AtlasClinicopathologic variablesMarker levelsClinical trialsStage ITherapeutic resistanceTCGA datasetA549 cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply